Gossamer Bio Target of Unusually Large Options Trading (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) was the target of some unusual options trading on Monday. Stock traders bought 23,621 call options on the company. This is an increase of approximately 882% compared to the typical volume of 2,406 call options.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its position in Gossamer Bio by 107.2% during the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after purchasing an additional 43,866 shares during the last quarter. Invesco Ltd. purchased a new position in Gossamer Bio in the first quarter worth about $48,000. Virtu Financial LLC bought a new position in shares of Gossamer Bio in the first quarter worth approximately $38,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Gossamer Bio during the first quarter valued at approximately $387,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Gossamer Bio during the first quarter valued at approximately $213,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Trading Up 3.7%

GOSS traded up $0.14 during trading on Monday, reaching $3.74. The stock had a trading volume of 6,036,664 shares, compared to its average volume of 2,504,695. The company has a market capitalization of $864.50 million, a price-to-earnings ratio of -5.41 and a beta of 1.92. The stock’s 50 day moving average is $2.75 and its two-hundred day moving average is $2.25. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $13.29 million for the quarter, compared to the consensus estimate of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. On average, equities research analysts predict that Gossamer Bio will post -0.28 earnings per share for the current year.

Wall Street Analysts Forecast Growth

GOSS has been the topic of several research analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Gossamer Bio in a research note on Thursday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Gossamer Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Gossamer Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.